Vaniprevir (Synonyms: MK-7009)

Cat. No.: HY-10243: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

For research use only. We do not sell to patients.

Vaniprevir Chemical Structure

CAS No. : 923590-37-8

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

1 Publications Citing Use of MCE Vaniprevir

•Personalized Medicine Universe. 2019 May.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	EC₅₀	0.27 nM Compound: MK-7009	Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	0.41 nM Compound: MK-7009	Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	0.7 nM Compound: MK-7009	Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	IC₅₀	19 nM Compound: 35b, vaniprevir, MK-7009	Antiviral activity against HCV Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs by replicon assay in presence of 50% normal human serum Antiviral activity against HCV Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs by replicon assay in presence of 50% normal human serum	[PMID: 20163176]
Huh-7	IC₅₀	19 nM Compound: 1, MK-7009	Antiviral activity against Hepatitis C virus (isolate Con1) genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs in presence of 50% NHS Antiviral activity against Hepatitis C virus (isolate Con1) genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs in presence of 50% NHS	[PMID: 24900473]
Huh-7	IC₅₀	3 nM Compound: 35b, vaniprevir, MK-7009	Antiviral activity against HCV Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs by replicon assay in presence of 10% fetal bovine serum Antiviral activity against HCV Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs by replicon assay in presence of 10% fetal bovine serum	[PMID: 20163176]
Huh-7	EC₅₀	5 nM Compound: MK-7009	Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay	[PMID: 20541424]
Huh-7	IC₅₀	9 nM Compound: 35b, vaniprevir, MK-7009	Antiviral activity against HCV JFH-1 infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs by replicon assay in presence of 10% fetal bovine serum Antiviral activity against HCV JFH-1 infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs by replicon assay in presence of 10% fetal bovine serum	[PMID: 20163176]

Clinical Trial

Molecular Weight

757.94

Formula

C₃₈H₅₅N₅O₉S

CAS No.

923590-37-8

Appearance

Solid

Color

White to off-white

SMILES

O=S(NC([C@@]1(NC([C@H]2N(C([C@@H](NC(OCC(CCCC3)(C)C)=O)C(C)(C)C)=O)C[C@H](OC(N4CC5=C3C=CC=C5C4)=O)C2)=O)C[C@H]1CC)=O)(C6CC6)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Purity & Documentation

Purity: 99.60%

Select Batch:

Data Sheet (276 KB) SDS (252 KB)

COA (257 KB) HNMR (231 KB) LCMS (320 KB)

Handling Instructions (2659 KB)

References

[1]. Liverton, Nigel J.; Carroll, Steven S.; Di Muzio, Jillian;.MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrobial Agents and Chemotherapy (2009), Volume Date 2010, 54(1), 305-311. [Content Brief]

[2]. Kong J, Chen CY, Balsells-Padros J, Cao Y, Dunn RF, Dolman SJ, Janey J, Li H, Zacuto MJ.Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.J Org Chem. 2012 Apr 20;77(8):3820-8. Epub 2012 Apr 10. [Content Brief]

[3]. Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; for the MK-7009 Protocol 007 Study Group.Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-na?ve patients with c [Content Brief]

[4]. Song ZJ, Tellers DM, Journet M, Kuethe JT, Lieberman D, Humphrey G, Zhang F, Peng Z, Waters MS, Zewge D, Nolting A, Zhao D, Reamer RA, Dormer PG, Belyk KM, Davies IW, Devine PN, Tschaen DM.Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-m [Content Brief]

[5]. McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ.Discove [Content Brief]

Vaniprevir Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vaniprevir923590-37-8MK-7009MK7009MK 7009HCVHCV ProteaseHepatitis C virusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks